Form SCHEDULE 13G - Statement of Beneficial Ownership by Certain Investors:
SEC Accession No. 0000950170-25-105905
Filing Date
2025-08-08
Accepted
2025-08-08 16:30:09
Documents
1

Document Format Files

Seq Description Document Type Size
1 primary_doc.html SCHEDULE 13G  
1 primary_doc.xml SCHEDULE 13G 4539
  Complete submission text file 0000950170-25-105905.txt   6419
Mailing Address 3 SUGAR CREEK CTR. BLVD. STE 525 SUGAR LAND TX 77478
Business Address 3 SUGAR CREEK CTR. BLVD. STE 525 SUGAR LAND TX 77478 (713) 489-8654
Tvardi Therapeutics, Inc. (Subject) CIK: 0001346830 (see all company filings)

EIN.: 000000000 | State of Incorp.: DE | Fiscal Year End: 1231
Type: SCHEDULE 13G | Act: 34 | File No.: 005-87880 | Film No.: 251198878
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)

Mailing Address 3139 WEST HOLCOMBE BLVD HOUSTON TX 77025
Business Address 3139 WEST HOLCOMBE BLVD HOUSTON TX 77025 1-800-491-9383
Sporos Bioventures LLC (Filed by) CIK: 0002072022 (see all company filings)

EIN.: 851294579 | State of Incorp.: DE | Fiscal Year End: 1231
Type: SCHEDULE 13G